Drug-resistant Bacterium Found In Eye Drops Has Infected 55 People In 12 States

Global News

Drug-resistant bacterium found in eye drops has infected 55 people in 12 states

A strongly drug-resistant bacterium has been found in multiple brands of artificial tears eyedrops; the most commonly reported was EzriCare Artificial Tears, sold by Walmart, Amazon and other retailers. The bacterium has infected 55 people throughout 12 US states, having killed one patient and leaving others hospitalised or with permanent vision loss.

The CDC has released an alert warning of the bacteria, although the FDA is yet to announce any product recalls. The CDC is recommending that clinicians and patients stop using the products in lieu of any official guidance from regulatory authorities.

EzriCare’s manufacturer has announced that it is planning to recall the product.

The bacterium is a strain of Pseudomonas aeruginosa, which is a very versatile, drug-resistant bacterium often found in freshwater. It can cause skin, wound, burn, lung and systemic infections, but most often affects immune-compromised people, for example those with cystic fibrosis.

Currently, 35 of the 55 infected were found in four clusters of cases within healthcare facilities, among these four clusters EzriCare was the only product consistent between them all.

The strain circulating at the moment is Verona Integron-mediated Metallo-ß-lactamase (VIM) and Guianan-Extended Spectrum-ß-Lactamase (GES)-producing carbapenem-resistant P. aeruginosa, also known as VIM-GES-CRPA. This is the first time VIM-GES-CRPA has spread in the US and it is resistant to countless antibiotics, including: cefepime, ceftazidime, piperacillin-tazobactam, aztreonam, carbapenems, ceftazidime-avibactam and various others. It currently appears that the strain is still susceptible to cefiderocol, a new antibiotic that received FDA approval in 2019.

Cases have so far been reported in California, Colorado, Connecticut, Florida, New Jersey, New Mexico, New York, Nevada, Texas, Utah, Washington and Wisconsin.

EzriCare has stated: “As of today, we are not aware of any testing that definitively links the Pseudomonas aeruginosa outbreak to EzriCare Artificial Tears. Nonetheless, we immediately took action to stop any further distribution or sale of EzriCare Artifical Tears. To the greatest extent possible, we have been contacting customers to advise them against continued use of the product.”

The company is so far cooperating with the CDC and FDA on the investigation.

Contaminated cough syrup leads to WHO Medical Product Alert

The WHO has shared a medical product alert for an additional contaminated cough syrup medicine identified in Africa.

New open innovation hub opened by Astellas for tumour microenvironment research

Astellas Pharma and Mitsui Fudosan have announced that Astellas plans to establish a tumour microenvironment (TME) open innovation hub, intended to open in October 2023.

Jemperli by GSK approved to treat endometrial cancer

GSK has announced that the FDA has approved Jemperli (dostarlimab) in combination with carboplatin and paclitaxel for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (DMMR) or microsatellite instability-high (MSI-H).

Alzheimer’s disease drug Leqembi given full approval by FDA

Japanese Eisai and US-based biotechnology company Biogen have announced that the FDA has given their Alzheimer’s disease drug Leqembi (lecanemab-irmb) full approval through the approval of a supplemental biologics license application.

First over the counter contraceptive pill approved by FDA

FDA has announced that it has approved the Opill (norgestrel) tablet for non-prescription use to prevent pregnancy.

Contaminated cough syrup leads to WHO Medical Product Alert

New open innovation hub opened by Astellas for tumour microenvironment research

Jemperli by GSK approved to treat endometrial cancer

Alzheimer’s disease drug Leqembi given full approval by FDA

First over the counter contraceptive pill approved by FDA

Pharmafocus

Categories

Social Footprints